Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 10/20 | 0.78 |
| ▸ | JAK3 | P52333 | 13/20 | 0.76 |
| ▸ | JAK2 | O60674 | 12/20 | 0.76 |
| ▸ | AURKA | O14965 | 4/20 | 0.76 |
| ▸ | RET | P07949 | 3/20 | 0.76 |
| ▸ | FLT3 | P36888 | 3/20 | 0.76 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.76 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.76 |
| ▸ | PTK2 | Q05397 | 2/20 | 0.76 |
| ▸ | TNK2 | Q07912 | 2/20 | 0.76 |
| ▸ | PTK2B | Q14289 | 2/20 | 0.76 |
| ▸ | PLK4 | O00444 | 1/20 | 0.76 |
| ▸ | STK10 | O94804 | 1/20 | 0.76 |
| ▸ | PAK4 | O96013 | 1/20 | 0.76 |
| ▸ | FER | P16591 | 1/20 | 0.76 |
| ▸ | CSNK2A2 | P19784 | 1/20 | 0.76 |
| ▸ | JAK1 | P23458 | 1/20 | 0.76 |
| ▸ | TYK2 | P29597 | 1/20 | 0.76 |
| ▸ | STAT3 | P40763 | 1/20 | 0.76 |
| ▸ | STAT5A | P42229 | 1/20 | 0.76 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4076083 | 0.88 | NTRK1 (1.00) | NTRK1JAK3JAK2AURKARET | |
| SCHEMBL3034183 | 0.87 | NTRK1 (0.71) | NTRK1JAK3JAK2AURKARET | |
| Azd-1480 SCHEMBL29523565 | 0.87 | JAK2 (1.00) | NTRK1JAK3JAK2AURKARET | |
| Azd-1480 SCHEMBL219103 | 0.87 | JAK2 (1.00) | NTRK1JAK3JAK2AURKARET | |
| Azd-1480 SCHEMBL3345019 | 0.87 | JAK2 (1.00) | NTRK1JAK3JAK2AURKARET | |
| Azd-1480 SCHEMBL220400 | 0.87 | JAK2 (1.00) | NTRK1JAK3JAK2AURKARET | |
| SCHEMBL29434985 | 0.87 | NTRK1 (0.73) | NTRK1JAK3JAK2AURKARET | |
| SCHEMBL588730 | 0.87 | NTRK1 (0.73) | NTRK1JAK3JAK2AURKARET | |
| SCHEMBL31060183 | 0.87 | NTRK1 (0.73) | NTRK1JAK3JAK2AURKARET | |
| SCHEMBL18281508 | 0.87 | NTRK1 (0.73) | NTRK1JAK3JAK2AURKARET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | claimed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | claimed |
| US-20080108633-A1 | Use 540 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | claimed |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ASTRAZENECA R&D (SE) | 2010-08-19 | — | — | US | disclosed |
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ASTRAZENECA AB (SE) | 2008-11-20 | — | — | US | disclosed |
| US-20080108633-A1 | Use 540 | ASTRAZENECA AB (SE) | 2008-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287437-A1 | Pyrazolylaminopyrimidine Derivatives Useful as Tyrosine Kinase Inhibitors | ABL1, FLT3, ERBB2 | NTRK1 574/4885JAK3 73/4885JAK2 32/4885 |
| US-20100210648-A1 | PYRAZOLYLAMINOPYRIMIDINE DERIVATIVES USEFUL AS TYROSINE KINASE INHIBITORS | ABL1, FLT3, ERBB2 | NTRK1 574/4885JAK3 73/4885JAK2 32/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.